Tocqueville Asset Management L.P. Sells 1,215 Shares of Edwards Lifesciences Co. (NYSE:EW)

Tocqueville Asset Management L.P. decreased its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 1.5% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 82,570 shares of the medical research company’s stock after selling 1,215 shares during the period. Tocqueville Asset Management L.P.’s holdings in Edwards Lifesciences were worth $6,113,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. FSA Wealth Management LLC bought a new stake in Edwards Lifesciences in the third quarter worth $30,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in shares of Edwards Lifesciences in the 4th quarter valued at about $30,000. Prospera Private Wealth LLC bought a new stake in shares of Edwards Lifesciences in the 3rd quarter valued at about $32,000. Avior Wealth Management LLC lifted its stake in shares of Edwards Lifesciences by 138.7% in the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 308 shares during the last quarter. Finally, Roble Belko & Company Inc bought a new position in Edwards Lifesciences during the 4th quarter worth approximately $46,000. Institutional investors own 79.46% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on EW shares. Canaccord Genuity Group raised their target price on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the stock a “hold” rating in a report on Thursday, February 13th. Piper Sandler boosted their price objective on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the company a “neutral” rating in a research report on Wednesday, February 12th. Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and increased their target price for the stock from $82.00 to $90.00 in a report on Monday, December 16th. Truist Financial restated a “hold” rating and set a $78.00 price target (up previously from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. Finally, Citigroup increased their price objective on Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $79.95.

Edwards Lifesciences Trading Down 0.5 %

Edwards Lifesciences stock opened at $70.31 on Wednesday. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The company has a market capitalization of $41.33 billion, a price-to-earnings ratio of 10.09, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12. The business’s fifty day simple moving average is $71.61 and its two-hundred day simple moving average is $70.35. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. As a group, equities analysts predict that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Bernard J. Zovighian sold 6,164 shares of Edwards Lifesciences stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $69.51, for a total value of $428,459.64. Following the completion of the sale, the chief executive officer now directly owns 59,083 shares in the company, valued at approximately $4,106,859.33. This trade represents a 9.45 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Daniel J. Lippis sold 500 shares of the company’s stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $68.76, for a total transaction of $34,380.00. Following the transaction, the vice president now owns 23,189 shares in the company, valued at $1,594,475.64. This represents a 2.11 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 51,303 shares of company stock worth $3,715,776 in the last three months. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.